tiprankstipranks
Capha Pharmaceuticals Inc. (FPSUF)
OTHER OTC:FPSUF
US Market
Holding FPSUF?
Track your performance easily

Capha Pharmaceuticals (FPSUF) Income Statement

1 Followers

Capha Pharmaceuticals Income Statement

Last quarter (Q3 2024), Capha Pharmaceuticals's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, Capha Pharmaceuticals's net income was C$-51.23K. See Capha Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-----C$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
C$ 50.95KC$ 71.72KC$ 75.37KC$ 56.17KC$ 68.02KC$ 86.77K
Operating Income
C$ -50.95KC$ -71.72KC$ -75.37KC$ -56.17KC$ -68.02KC$ -86.77K
Net Non Operating Interest Income Expense
------
Other Income Expense
--C$ -539.00C$ -6.00C$ -603.00C$ 137.00
Pretax Income
C$ -51.23KC$ -72.02KC$ -75.91KC$ -56.17KC$ -68.62KC$ -86.63K
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -51.23KC$ -72.02KC$ -75.91KC$ -56.17KC$ -68.62KC$ -86.63K
Basic EPS
-----C$ >-0.01
Diluted EPS
-----C$ >-0.01
Basic Average Shares
C$ 64.43MC$ 64.43MC$ 64.43MC$ 64.43MC$ 64.43MC$ 64.43M
Diluted Average Shares
C$ 64.43MC$ 64.43MC$ 64.43MC$ 64.43MC$ 64.43MC$ 64.43M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 71.06KC$ 71.72K---C$ 86.77K
Interest Expense
------
Net Income From Continuing And Discontinued Operation
C$ -51.23KC$ -72.02KC$ -75.91KC$ -56.17KC$ -68.62KC$ -86.63K
Normalized Income
C$ -78.67KC$ -52.94KC$ -55.79KC$ -41.29KC$ -50.08KC$ -86.77K
EBIT
C$ -121.53KC$ -72.02KC$ -75.91KC$ -56.17KC$ -68.62KC$ -86.77K
EBITDA
C$ -121.39KC$ -71.83KC$ -75.64KC$ -55.79KC$ -67.97KC$ -85.86K
Currency in CAD

Capha Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis